The FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.

Rare functional sugars provide huge market opportunities. European Biotechnology spoke with Stefan Jennewein, Founder and CEO of Jennewein Biotechnologies, about the company’s strategy and its latest expansions to the Chinese market.

Novel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the company’s expansion.

At BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.

Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.

EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation.

Evotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m.

Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer

Researchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.

In an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.